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Abstract
Background: Previous studies showed that a naturally attenuated strain from Trypanosoma cruzi triggers an immune
response mainly related to a Th2-type profile. Albeit this, a strong protection against virulent challenge was
obtained after priming mice with this attenuated strain. However, this protection is not enough to completely
clear parasites from the host. In T. cruzi infection, early Interferon-gamma (IFN-γ) is critical to lead type 1
responses able to control intracellular parasites. Therefore we evaluated whether the co-administration of a
plasmid encoding murine IFN-γ could modify the immune response induced by infection with attenuated
parasites and improve protection against further infections.
Methods: C57BL/6J mice were infected intraperitoneally with three doses of live attenuated parasites in
combination with plasmid pVXVR-mIFN-γ. Before each infection dose, sera samples were collected for
parasite specific antibodies determination and cytokine quantification. To evaluate the recall response to T.
cruzi, mice were challenged with virulent parasites 30 days after the last dose and parasite load in
peripheral blood and heart was evaluated.
Results: As determined by ELISA, significantly increase in T. cruzi specific antibodies response was detected in the group
in which pVXVR-mIFN-γ was incorporated, with a higher predominance of IgG2a subtype in comparison to the group of
mice only inoculated with attenuated parasites. At our limit of detection, serum levels of IFN-γ were not
detected, however a slight decrease in IL-10 concentrations was observed in groups in which pVXVR-mIFN-γ
was supplemented. To analyze if the administration of pVXVR-mIFN-γ has any beneficial effect in protection
against subsequent infections, all experimental groups were submitted to a lethal challenge with virulent
bloodstream trypomastigotes. Similar levels of challenge parasites were detected in peripheral blood and
heart of mice primed with attenuated parasites alone or combined with plasmid DNA. Expansion of IgG
antibodies was not significant in TCC+ pVXVR-mIFN-γ; however, the overall tendency to sustain a Th2
profile was maintained.
Conclusions: Overall, these results suggest that administration of plasmid pVXVR-mIFN-γ could have beneficial effects
on host specific antibody production in response to T. cruzi attenuated infection; however, this outcome is not reflected
in an improved protection against further virulent infections.
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Background
Trypanosoma cruzi is a kinetoplastid parasite capable of
infecting mammalian hosts leading in humans to the de-
velopment of a number of clinical manifestations known
as Chagas disease. This endemic disorder is of great im-
portance in Central and South America since several
million people are infected [1]. However, in recent years
the increasing percentage of infected people in non-
endemic areas due to migration influx has been a major
focus of attention [2]. Chagas disease presents broad
immunopathological profiles, ranging from asymptho-
matic cases; single digestive forms with megaesophagus
and megacolon; single cardiac forms with intense
myocarditis; or digestive and cardiac forms appearing to-
gether [3, 4]. Several years after infection, 30–40% of the
infected persons develop progressive irreversible tissue
damage. Currently, chemotherapy for Chagas disease pa-
tients is limited to the administration of benznidazole or
nifurtimox. These drugs are highly effective in the acute
phase, in congenital cases and in children with chronic
infection, however; recent studies indicate a limitation in
the efficacy of these drugs in chronic adults [5]. In most
of the cases, people receiving drug therapy interrupt the
treatment as a result of the severity of the side effects as-
sociated to nitro compounds [6]. Additionally, restriction
of people living in endemic areas to the closer health
centers deprives them from receiving a prompt diagnosis
and the adequate treatment [7]. For many parasitic
diseases, vaccines had the potential to overcome these
misfortunes. Several immunoprophylactic as well as
immunotherapeutic attempts have been made in order
to prevent T. cruzi establishment and persistence in the
host [8–12]. Still, to date, there is no vaccine licensed for
Chagas disease, neither for humans nor for veterinary
use.
In T. cruzi infection, the innate and adaptive immune
responses play a crucial role in parasite control. These
responses involve macrophages, natural killer (NK) cells,
T and B lymphocytes, and the production of pro-
inflammatory Th1 cytokines such as Interferon gamma
(IFN-γ), Tumor Necrosis Factor Alpha (TNF-α) and
interleukin 12 (IL-12) [13]. Also, the recognition of
pathogen-associated molecular patterns (PAMP) by Toll
Like receptors (TLRs), guides for activation of B and T
cells, highlighting the important role of TLRs in con-
necting innate and acquired immunity [14]. IFN-γ is a
key cytokine, secreted by NK cells and other cell types
upon IL-12 generation, which has been shown to be cru-
cial in guiding the development of naïve CD4+ T cells to-
wards a Th1 phenotype as well as activating
macrophages for the production of nitric oxide which is
responsible for parasite clearance [15–17]. CD8+ T cells
also secrete IFN-γ and their importance on parasite con-
trol has been well documented [18–20]. Still, it was
recently shown that Th17 cells, another subset of CD4+
T cells, confer significantly stronger protection against
T. cruzi than even Th1 cells [21]. In any event, the role
of IFN-γ in controlling intracellular parasite infections is
crucial. Despite the response orchestrated, T. cruzi can
induce IL-10 production by dendritic cells and persist
indefinitely in the host [22, 23].
It has been described that the naturally attenuated
TCC strain from T. cruzi triggers a Th2-type immune
profile in contraposition to virulent strains which are
mainly related to a Th1-type one [24]. Albeit the Th2-
type outline triggered by TCC infection, this attenuated
strain has been extensively used by our group in prime/
boost/challenge experiments [25–31]. This evaluation
was also extended to genetically modified mutant clones
from this same strain [32, 33]. Even though protection
against further infections is strong enough to control
parasite replication, is not sufficient to completely clear
the parasites from the host. With this in mind we won-
dered if the addition of an external source of IFN-γ
could change or improve the immunological and pro-
tective effect of attenuated TCC parasites. In this work,
we describe the enhancement in the specific antibody re-
sponses of mice after infection with TCC attenuated par-
asites co-administered with plasmid DNA encoding
murine IFN-γ. However, this upgrade in the particular
humoral response elicited did not correlate with a sig-
nificant reduction in parasite burden after challenge with
virulent parasites.
Methods
Parasites and plasmid preparation
For the infection assays, metacyclic trypomastigotes
from the naturally attenuated TCC strain from T. cruzi
were used [34]. Briefly, epimastigotes were grown at 28 °
C in liver digested neutralized tryptose medium (LDNT),
supplemented with 10% fetal bovine serum (FBS) until
they reached log-phase. Metacyclics trypomastigotes
were then obtained by epimastigotes differentiation
under chemically defined conditions (TAU 3AAG
medium). Complement resistant forms were purified
using normal non decomplemented serum, quantified in
a Neubauer chamber and further used to inoculate ex-
perimental animals. Virulent blood trypomastigotes
forms from the Tulahuen strain were prepared by rou-
tinely biweekly passage through BALB/c mice. The
eukaryotic expression plasmid pVXVR-mIFN-γ was gen-
tly donated by Dr. Gomez Hernandez from Brazil. Con-
cisely, mIFN-γ was amplified from splenocytes cDNA
previously stimulated with lipopolysaccharides (LPS) and
then cloned in pVXVR plasmid, a fusion between plas-
mids pCDNA3 and VR1012. Final construction,
pVXVR-mIFN-γ was transformed into Escherichia coli
DH5α competent cells, grown in LB media containing
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100 μg/ml ampicillin, and purified by anion-exchange
chromatography using the Endo-free Qiagen maxiprep
kit (Qiagen) as per manufacturer recommendations and
then quantified using Nanodrop 2000 (Thermo
Scientific).
Infection in mice
Six to 8 week old male C57BL/6 J mice were used
throughout these studies. Parasites and plasmid DNA
were administered intraperitoneally (IP). For this, 105
purified metacyclic trypomastigotes/mouse from the
TCC strain were used and/or 50 μg/mouse of plasmid
pVXVR-mIFN-γ according to the particular experiment.
Three doses were delivered at 4-week intervals. Control
groups consisting of empty plasmid and non-infected
animals were included in the experiment.
T. cruzi-specific IgGs ELISA
During the infection period with attenuated parasites
and plasmid DNA, serum samples were collected and al-
iquots were maintained at −80 °C until use for IgGs de-
termination. Total immunoglobulin G antibodies (1:2500
dilution-SIGMA-ALDRICH) against T. cruzi were mea-
sured by the enzyme-linked immunosorbent assay
(ELISA) using T. cruzi epimastigote homogenate as anti-
gen (1 μg/100 μl-Coating Buffer/well). To identify the
antibody subtypes, plates were coated as above, blocked
with Phosphate Buffer Solution (PBS) 5% non-fat dry
milk, and then incubated with serum samples (1∶100
dilution, 100-μl/well) for 1 h, biotin-conjugated goat
anti-mouse Ig subtypes (IgG1 or IgG2a-1:3500 dilution-
BD Pharmigen) for 1 h, and streptavidin-horseradish
peroxidase conjugate (BD-Pharmigen) for 1 h at 37 °C.
Color was developed with TMB Substrate Reagent Set
(BD-Pharmigen) and monitored at 450 nm using a
Tecan Infinite Pro microplate reader.
Spleen cells culture supernatant
Spleens were removed from euthanized infected mice,
macerated on a sterile mesh, and cells were resuspended
in RPMI 1640 medium. Following centrifugation at
160×g for 10 min at 4 °C, the cells were resuspended in
a lysis solution (0.17 M Tris pH 7.2, 0.16 M NH4Cl) to
remove erythrocytes. The remaining splenocytes were
washed three times with RPMI and resuspended in
RPMI supplemented with 20 mM glutamine, 10%
NaHCO3 and 10% fetal bovine serum. Viability of cells
was assessed by Trypan blue exclusion and cell number
was determined in a Neubauer chamber. Splenocytes
(106cells/well in triplicate) were cultured for 48 h at 37 °
C and 5% CO2, with or without stimulation with 25 μg/
mL of T. cruzi epimastigote homogenate or with 50 μg/
mL of Phytohaemagglutinin (PHA). Cell culture medium
was then collected and aliquots stored at −80 °C until
use for cytokines determination.
Cytokine response
Sera samples as well as splenocytes culture supernatant
were used for cytokines’ measurement (IL-10, TNF-α
and IFN-γ) using optEIA enzyme-linked immunosorbent
assay (ELISA) kits (BD-Pharmingen), according to the
manufacturer’s specifications.
Survival rate and parasitemia
To evaluate the recall response to T. cruzi, mice were
challenged with T. cruzi Tulahuen strain (500 blood try-
pomastigotes/mouse, IP). Biweekly, blood (10 μl) was
drawn from the tail tip of mice under slight anesthesia,
and the number of parasites per 100 fields (parasitemia)
was recorded from fresh blood mounts under micro-
scope (×400). Mortality was checked daily until 30 days
post challenge and expressed as percentage of survival.
Tissue parasite burden
Thirty days post virulent challenge mice were sacrificed
by carbon dioxide (CO2) overexposure. At this point
serum samples were taken for determining IgGs expan-
sion and cytokines responses. Heart samples were taken
for parasite DNA quantification. Total DNA from heart
tissue (50 mg) was isolated using the ADN-Puriprep
Highway nucleic acid kit (InbioHighway), according to
instructions provided by the manufacturer. Total DNA
(10 ng) was used as a template, and real-time PCR per-
formed on a LineGene 9640 Sequence Detection System
(BIOER) with SYBR Green Supermix (Biosystems) and
Tc18SrDNA-specific oligonucleotides (SAT_F 5’GCAG
TCGGCKGATCGTTTTCG-3′ and SAT_R 5’TTCAG
RGTTGTTTGGTGTCCAGTG-3′). Data were normal-
ized to murine TNF-α (TNF_F 5′-TCCCTCTCATCA
GTTCTATGGCCCA-3′ and TNF_R 5’CAGCAAG-
CATCTATGCACTTAGACCCC-3′).
Statistical analysis
Continuous variables, such as antibody levels and
parasite concentrations in blood samples, were ana-
lyzed with the two-tailed Wilcoxon signed-rank test
for time course plots and with the Mann-Whitney or
Kruskal-Wallis test for single-day measurements with
Dunn’s Multiple Comparison Test. Values are
expressed as mean with standard errors of the mean
(SEM) from at least three independent experiments.
Differences between two groups were considered sig-
nificant and are shown by *p 0.05, **p 0.01,
***p 0.001.
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Results
IFN-γ production alters the specific immune response
elicited by attenuated parasites
To determine the levels of T. cruzi-specific IgGs after in-
fection with attenuated parasites, serum samples were
collected 30 days after each dose. As determined by
ELISA, parasite specific antibodies levels increased after
each boost and were significantly elevated in the group
in which pVXVR-mIFN-γ was co-administered in com-
bination with attenuated parasites when compared to
the TCC infected group (Fig. 1a, *p < 0.05). To indirectly
evaluate the impact of pVXVR-mIFN-γ administration
on the effector cytokine pattern during infection with at-
tenuated parasites, the levels of parasite specific IgG
subtypes were determined by ELISA. IgG1 antibodies
were primarily detected in TCC-infected animals with
significantly low predominance of IgG2a (Fig. 1b); how-
ever when pVXVR-mIFN-γ plasmid was administered, a
balance between IgG1 and IgG2a was observed with a
significantly increase in anti-T. cruzi IgG2a antibodies
when compared to TCC-infected animals (Fig. 1b, *p <
0.05, TCC vs TCC+ pVXVR-mIFN-γ). Because the
switch towards a different subtype could be promoted
by various cytokines, serum concentrations of regulatory
(IL-10) and pro-inflammatory (IFN-γ) cytokines were
measured. We observed that sustained boosts with TCC
parasites combined with plasmid DNA resulted in in-
creased production of IL-10. However, when pVXVR-
mIFN-γ is added, the concentration of IL-10 at different
time points tended to be slightly lower (Fig. 1c, *p <
0.05). IFN-γ levels were found below the detection limit
of the technique in all of the tested samples. Spleen cells
from TCC and TCC + pVXVR-mIFN-γ infected animals
were also analyzed. Cells were stimulated for 48hs with
T. cruzi antigen and the levels of IFN-γ and IL-10 were
determined in culture supernatant (Fig. 1d). As in serum
samples, IFN-γ was not detected at significant levels. IL-
10 production by splenocytes was similar in TCC and in
TCC + pVXVR-mIFN-γ infected animals but different
from pVXVR-mIFN-γ administered animals or naïve
ones. Interesting to note is that naïve animals exhibited
a lower level of IL-10 compared to animals receiving
pVXVR-mIFN-γ possibly indicating that the presence of
the IFN-γ plasmid could be rendering for a lower pro-
duction of IL-10 by spleen cells. From these results is
evident to conclude that the addition of pVXVR-mIFN-γ
a b
c d
Fig. 1 pVXVR-mIFN-γ administration alters the parasite-specific immune response elicited by infection with attenuated parasites. Mice (n = 4) were
infected (4 weeks apart) with 3 doses of 105 metacyclic trypomatigotes of the attenuated TCC strain, 50 μg of plasmid pVXVR-mIFN-γ or a com-
bination of both. After each infection dose, serum samples were collected for IgG and cytokines determination. a T. cruzi specific total IgGs levels;
b serum levels of parasite specific IgG subtypes, c IL-10 measurement determined by ELISA and (d) IL-10 and IFN-γ levels in supernatant from T.
cruzi stimulated spleen cells. Data are representative of three independent experiments. * p < 0.05 Kruskal-Wallis test for single-day measurements
with Dunn’s Multiple Comparison Test
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may favor the expansion of the specific IgG response
mounted by the prime infection with TCC attenuated
parasites. Even more, a tendency in altering the IgG sub-
type levels (increased in IgG2a profile) and IL-10 pro-
duction was observed after plasmid addition, indicating
that it would be possible to redirect the Th2-type pheno-
type obtained by the infection with TCC attenuated par-
asites towards a mixed Th1/Th2 profile.
TCC + pVXVR-mIFN-γ elicited protection against in vivo
lethal challenge and parasite replication in heart
To analyze if the immune response elicited by the ad-
ministration of plasmid pVXVR-mIFN-γ in conjunc-
tion with live attenuated parasites was protective, all
experimental groups were submitted to a lethal chal-
lenge with virulent bloodstream trypomastigotes. Ani-
mals were infected 30 days after the last dose with
attenuated parasites alone or in combination with
plasmid pVXVR-mIFN-γ and parasites level recorded
every week during the acute phase. Survival was mon-
itored daily and all mice from control groups suc-
cumbed to death after day 30 post challenge (Fig. 2a).
Meanwhile, TCC and TCC + pVXVR-mIFN-γ groups
showed 100% survival until the end of follow-up. The
level of circulating parasites in peripheral blood from
TCC or TCC + pVXVR-mIFN-γ infected animals was
scarcely detectable (Fig. 2b). In this model and with
this technique, the advantage of administrating
pVXVR-mIFN-γ or not was not evident since no sta-
tistically significant differences were found between
both groups. However, parasitemia from these groups
was significantly different from the control groups
(Fig. 2b, **p < 0.01). Real time PCR outcome verified
the above mentioned results, since a significant re-
duction in parasite-specific Tc18SrDNA signal in
heart of TCC and TCC + pVXVR-mIFN-γ infected
animals was detected when compared to control
groups (Fig. 2c, *p < 0.05 in TCC and TCC+ pVXVR-
mIFN-γ vs pVXVR-mIFN-γ). Also with this technique
the advantages of introducing pVXVR-mIFN-γ were
not evident since no significant differences with TCC
primed animals were detected.
Parasite specific immune response is expanded in reply
to T. cruzi virulent infection
In order to evaluate the antibody response elicited in
primed animals after challenge with virulent parasites,
serum samples were collected 30 days post infection.
TCC infected animals exhibited a significant expan-
sion of parasite specific IgG in response to T. cruzi
virulent infection (Fig. 3a, *p < 0.05). However, in the
case in which pVXVR-mIFN-γ was co-administered
together with attenuated parasites, expansion was sig-
nificantly diminished. Although not significant, the
IgG1 response in TCC + pVXVR-mIFN-γ primed/chal-
lenged animals was lower than in TCC primed/chal-
lenged group. IgG2a was to some extent expanded in
the case in which pVXVR-mIFN-γ was added, and di-
minished in TCC-primed mice (Fig. 3b). These data
suggested that TCC-primed elicited a parasite-specific
IgG response upon challenge infection and that
addition of plasmid pVXVR-mIFN-γ, even not con-
tributing to this expansion, may favor the guidance
towards a Th1 phenotype. Serum concentrations of
IL-10, TNF-α and IFN-γ cytokines were also mea-
sured after virulent challenge. The levels of IFN-γ
and TNF-α were similar in TCC or TCC + pVXVR-
IFN-γ primed/challenged animals in comparison to
non-primed animals (Fig. 4a-c). However, unchanged
values for IL-10 production were detected among all
experimental groups (Fig. 4b).
a b c
Fig. 2 Control of parasite replication in animals primed with TCC+ pVXVR-mIFN-γ after lethal challenge. Thirty days after the last dose with attenu-
ated parasites and plasmid DNA, animals were challenged with 500 blood trypomastigotes from the Tulahuen strain (n = 4). a Survival rate during
the challenge period; b parasite load in peripheral blood as determined by fresh blood mount and (c) parasite load in heart as determined by
Real Time PCR 30 days post challenge. Data are representative of three independent experiments. * p < 0.05 and ** p < 0.01 Kruskal-Wallis test for
single-day measurements with Dunn’s Multiple Comparison Test
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Discussion
It is known that during the course of many infections,
initial IFN-γ production is fundamental and may be im-
portant in the development of resistance to many intra-
cellular infections such as the one produced by T. cruzi.
Also, the activation of the specific cells responsible for
the production of this cytokine requires the presence of
live parasites [35]. In an attempt to elucidate if parasite
specific immune response could be modified or im-
proved, we decided to co-administer, together with
highly attenuated parasites, a eukaryotic expression plas-
mid encoding the murine sequence of the cytokine IFN-
γ. Our principal observation is that the addition of the
plasmid containing IFN-γ significantly improves the gen-
eration of parasite specific antibodies in response to
prime infection. It is well known that early secreted
IFN-γ by NK cells activates plasma B cells to produce
antibodies in order to lyse extracellular trypomastigotes
or to facilitate the opsonization process. Therefore the
effect of early introducing a source of IFN-γ fostering
the natural generation of parasite specific antibodies
upon infection is beneficial as demonstrated by our re-
sults. The importance of IFN-γ in the generation of a
Th1 response and in the formation of IFN-γ-dependent
IgG2a antibodies has been demonstrated since parasite
specific antibody response of infected IFN-γ-KO mice
was restricted to IgG1 antibodies, being parasite specific
IgG2a antibodies absent [36]. TCC-primed animals pre-
sented a larger predominance of IgG1 rather than IgG2a
antibodies; however, with IFN-γ plasmid administration,
this phenotype could be slightly biased towards a Th1/
Th2 balance with reduced values of IgG1a and enlarged
levels of IgG2a. This switch of Ig-isotype to cytophilic
and complement-fixing IgG2a antibodies has also been
demonstrated to be induced by IFN-γ [37]. Even more,
these same results were observed in other infections as-
says following the same experimental design, in which
attenuated parasites and plasmid DNA were adminis-
tered oral or intramuscularly, indicating that the admin-
istration route, especially for plasmid DNA, does not
modify the results herein presented (Additional file 1:
Figure S1).
When a host has been immunized, either by infection
or vaccination, one of the most important parameters to
be measured is its capacity to respond against a subse-
quent infection. All immunized animals were protected
a b
Fig. 3 Expansion of immune specific antibodies in response to T. cruzi infection. Thirty days after challenge serum samples from animals primed
with TCC, TCC+ pVXVR-IFN-γ, pVXVR-IFN-γ and PBS were collected for (a) parasite specific IgG antibodies and (b) IgG subtypes by ELISA. Data are
representative of three independent experiments. * p < 0.05 Kruskal-Wallis test for single-day measurements with Dunn’s Multiple
Comparison Test
a b c
Fig. 4 Cytokines levels in response to virulent T. cruzi infection. Cytokine concentration in serum of TCC and TCC+ pVXVR-IFN-γ primed animals
challenged with virulent parasites. Samples were collected 30 days post challenge and cytokines level measured by ELISA for (a) IFN-γ, (b) IL-10
and (c) TNF-α. Data are representative of three independent experiments. * p < 0.05 Kruskal-Wallis test for single-day measurements with Dunn’s
Multiple Comparison Test
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against death, with 100% of these mice surviving the le-
thal challenge. Virulent infection of primed animals with
a lethal dose of bloodstream trypomastigotes led to sig-
nificantly decreased parasitemias and parasite load in
heart samples in all the groups infected with attenuated
parasites, regardless administration or not of plasmid
coding for IFN-γ. Interesting to note is that previous ad-
ditions of pVXVR-mIFN-γ solely and later infection with
virulent parasites resulted, in some extent, in exacer-
bated parasite load in blood as well as in heart samples,
suggesting that unregulated IFN-γ inner production
could be unfavorable for the host. These results are sup-
ported by the observation that parasite load in mice in-
oculated with naked plasmid and later infected with
virulent parasites resulted in values similar or lower than
the control group inoculated with PBS and challenged
later (data not shown). All together, these results indi-
cate that infection with attenuated parasites per se is ef-
ficient in regulating parasite burden in target organs and
peripheral blood and, that the combined administration
of pVXVR-mIFN-γ has no significant role in helping
controlling parasite replication at this time point.
Challenged infection resulted in a rapid and potent ex-
pansion of parasite specific antibody response in TCC-
infected animals; however this expansion is not favored
by pVXVR-mIFN-γ addition. One possible explanation
for this observation maybe that upregulation of FcR by
IFN-γ activated macrophages [38] is augmented by an
additional source of IFN-γ, increasing the captured of
opsonized parasites, therefore requiring the availability
of a larger amount of parasite specific antibodies. Never-
theless, a considerable level of T. cruzi specific anti-
bodies was detected in the group of animals primed with
pVXVR-mIFN-γ plasmid alone, indicating that mice
which have never seen T. cruzi antigen before but were
stimulated with plasmid carrying IFN-γ posses the cap-
acity to better respond, at least at the humoral level, to a
subsequent virulent infection. This last result is also sup-
ported by the fact that animals primed with empty plas-
mid and later challenged with virulent parasites
presented antibodies levels similar to control group in-
oculated with PBS. The predominance of a Th1 pheno-
type in expanded specific IgGs is maintained by pVXVR-
mIFN-γ supply during infection with attenuated para-
sites, as well as after challenge infection. Since it was re-
ported that IgG2a antibodies efficiently mediates
clearance of blood trypomastigotes [39], the increase in
anti–T. cruzi IgG2a subtype antibodies after challenge of
primed animal could be important to reduce parasite
proliferation. Additionally, the assessment of the cyto-
kines profile also showed differences among groups. At
30 days post challenge, the levels of IFN-γ and TNF-α in
primed animals were lower in comparison to non-
primed animals (pVXVR and PBS group). This finding
was in concordance with the level of circulating parasites
in peripheral blood at this time point, suggesting that
IFN-γ and TNF-α production in TCC and TCC +
pVXVR- IFN-γ primed-animals was not longer necessary
since parasite clearance already occurred. The elevated
levels of TNF-α found within the non-primed groups
could have a harmful effect in the host, exacerbating the
existing inflammatory response. It has been demon-
strated that TNF-α increased during early T. cruzi infec-
tion is associated to the induction of trypanomicide
mechanisms and tissue injury [40]. In this regard, we
suggest that a modulated amount of IFN-γ and TNF-α
secreted after a virulent challenge could be related to a
controlled response against the antigen, meanwhile, an
exacerbation of this response with elevated levels of both
cytokines, as we have shown in the control groups could
be responsible for inflammation and consequent tissue
damage. Interestingly, in our experiments, IL-10 produc-
tion did not differ among groups. Similar results were
observed by others, in which chronically infected/chal-
lenged mice only showed IL-10 production after day 7
post challenge, reaching later, to levels similar to those
found in non infected/challenged mice. These authors
suggest that IL-10 production, as IFN-γ production of
chronically infected mice depends on intense proinflam-
matory signals induced by parasites [41].
Besides stimulating B cells, perhaps the most notice-
able effect that IFN-γ exerts is the enhancement of mi-
crobicidal activity by stimulating macrophages to
produce Nitric Oxide (NO) and kill intracellular amasti-
gotes. This evidence has recently been confirmed by
means of “Macrophage Insensitive to Interferon
Gamma” KO mice, since macrophages from these ani-
mals were unable to produce NO and kill intracellular
parasites upon challenge and after priming with IFN-γ
[42]. On the other hand, the impact of IFN-γ in the
modulation of chemokine expression in vivo has awak-
ened attention [43]. Therefore, it is quite obvious to pos-
tulate that other immune mechanisms, beyond the ones
herein studied, might had taken place during this
immunization process leading to an improved activation
and priming of immune specific cells capable of control-
ling parasite spread.
Conclusions
In summary we conclude that TCC + pVXVR-mIFN-γ
infection successfully primed B cells and induced high
parasite specific antibody response with a Th1/Th2
phenotype able to protect against a virulent challenge.
However, this increase in the specific antibody response,
due to pVXVR-mIFN-γ addition, is not enough to im-
prove the control of parasite replication and persistence
in the host. Basic immunological studies indicate that
antibodies solely are not enough to manage T. cruzi
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infection and that parasite control relies mostly on a cel-
lular immune response with predominance of activation
of CD8+ T cells [18, 19, 44]. In a previous work we
showed that CD8+ T cells were induced by infection
with TCC attenuated parasites [32] thus we supposed
that this response could be very likely strengthened by
endogenous IFN-γ production and expanded after viru-
lent challenge. Licensed vaccines against many patho-
gens confer protection by stimulating B cells to produce
a wide repertoire of pathogen-specific antibodies. Our
most striking observation herein presented, that T.
cruzi–specific humoral responses elicited by attenuated
parasites can be optimized and presumably switch to-
wards a Th1/Th2 balance by plasmid encoding IFNγ
supplementation, addresses the possibility that other
immune-boosting strategies, for therapeutic or immune-
prophylactic vaccines approaches, should be deeper in-
quired into. The results herein presented emphasized
the fact that a T. cruzi vaccine should be addressed from
a multicomponent point of view, properly activating the
humoral and cellular responses needed for protection.
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attenuated TCC strain, 50 μg of plasmid pVXVR-mIFN-γ or a combination
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dose, serum samples were collected for (A-B) T. cruzi specific total IgGs
levels and (C-D) serum levels of parasite specific IgG subtypes. (PDF
48 kb)
Abbreviations
CO2: Carbon dioxide; ELISA: Enzyme-linked immunosorbent assay; FBS: Fetal
bovine serum; IFN-γ: Interferon gamma; IL: Interleukin; IP: Intraperitoneally;
LDNT: Liver digested neutralized tryptose medium; LPS: Lipopolysaccharides;
NK: Natural killer; NO: Nitric Oxide; PAMP: Pathogen-associated molecular
patterns; PBS: Phosphate Buffer Solution; PHA: Phytohaemagglutinin;
SEM: Standard errors of the mean; TLRs: Toll Like receptors; TNF-α: Tumor
Necrosis Factor Alpha
Acknowledgements
We are grateful to Maria Celia Mora for animal care and supervision and to
Alejandro Uncos, Renato Uncos and Federico Ramos for skillful technical
assistance.
Funding
This work was supported by grants Fundación Florencio Fiorini and PICT
2014–1625 to CPB. The funders had no role in the design of the study and
collection, analysis, and interpretation of data and in writing the manuscript.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article.
Authors’ contributions
CPB and MAB conceived and designed the experiments. CPB, ACM, CP, ROC
and CaPB performed the experiments. CPB, ACM and CP analyzed the data.
CPB, CaPB and PD contributed reagents/materials/analysis tools. CPB wrote
the manuscript. All authors revised the manuscript intensively and approved
its final version.
Ethics approval
All animal protocols adhered to the National Institutes of Health (NIH) “Guide
for the care and use of laboratory animals” and were approved by the
School of Health Sciences and by the Ethical Committee of the National




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Instituto de Patología Experimental, Consejo Nacional de Investigaciones
Científicas y Técnicas (CONICET), Universidad Nacional de Salta, Salta-Capital,
Argentina. 2Instituto de Investigación de Enfermedades Tropicales, Sede
Regional Orán. Universidad Nacional de Salta, Salta-Capital, Argentina.
3Estación Experimental Agropecuaria Salta, Instituto Nacional de Tecnología
Agropecuaria (INTA), Salta-Capital, Argentina.
Received: 23 June 2017 Accepted: 15 November 2017
References
1. Stanaway JD, Roth G. The burden of Chagas disease: estimates and
challenges. Glob Heart. 2015;10(3):139–44.
2. Liu Q, Zhou XN. Preventing the transmission of American trypanosomiasis
and its spread into non-endemic countries. Infect Dis Poverty. 2015;4:60.
3. Bilate AM, Cunha-Neto E. Chagas disease cardiomyopathy: current concepts
of an old disease. Rev Inst Med Trop Sao Paulo. 2008;50(2):67–74.
4. Coura JR, Borges-Pereira J. Chagas disease: 100 years after its discovery. A
systemic review. Acta Trop. 2010;115(1–2):5–13.
5. Pecoul B, Batista C, Stobbaerts E, Ribeiro I, Vilasanjuan R, Gascon J, Pinazo
MJ, Moriana S, Gold S, Pereiro A, et al. The BENEFIT trial: where do we go
from here? PLoS Negl Trop Dis. 2016;10(2):e0004343.
6. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A.
Side effects of benznidazole as treatment in chronic Chagas disease: fears
and realities. Expert Rev Anti-Infect Ther. 2009;7(2):157–63.
7. Pinheiro E, Brum-Soares L, Reis R, Cubides JC. Chagas disease: review of
needs, neglect, and obstacles to treatment access in Latin America. Rev Soc
Bras Med Trop. 2017;50(3):296–300.
8. Perez Brandan C, Basombrio MA. Genetically attenuated Trypanosoma cruzi
parasites as a potential vaccination tool. Bioengineered. 2012;3(4):242–6.
9. Quijano-Hernandez I, Dumonteil E. Advances and challenges towards a
vaccine against Chagas disease. Hum Vaccin. 2011;7(11):1184–91.
10. Rodriguez-Morales O, Monteon-Padilla V, Carrillo-Sanchez SC, Rios-Castro M,
Martinez-Cruz M, Carabarin-Lima A, Arce-Fonseca M. Experimental vaccines
against Chagas disease: a journey through history. J Immunol Res. 2015;
2015:489758.
11. Sanchez-Valdez FJ, Perez Brandan C, Ferreira A, Basombrio MA. Gene-
deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect
against Chagas disease. Expert Rev Vaccines. 2015;14(5):681–97.
12. Vazquez-Chagoyan JC, Gupta S, Garg NJ. Vaccine development against
Trypanosoma cruzi and Chagas disease. Adv Parasitol. 2011;75:121–46.
13. Junqueira C, Caetano B, Bartholomeu DC, Melo MB, Ropert C, Rodrigues
MM, Gazzinelli RT. The endless race between Trypanosoma cruzi and host
immunity: lessons for and beyond Chagas disease. Expert Rev Mol Med.
2010;12:e29.
14. Rodrigues MM, Oliveira AC, Bellio M. The immune response to Trypanosoma
cruzi: role of toll-like receptors and perspectives for vaccine development. J
Parasitol Res. 2012;2012:507874.
15. Antunez MI, Cardoni RL. IL-12 and IFN-gamma production, and NK cell
activity, in acute and chronic experimental Trypanosoma cruzi infections.
Immunol Lett. 2000;71(2):103–9.
16. Gutierrez FR, Mineo TW, Pavanelli WR, Guedes PM, Silva JS. The effects of
nitric oxide on the immune system during Trypanosoma cruzi infection.
Mem Inst Oswaldo Cruz. 2009;104(Suppl 1):236–45.
Pérez Brandán et al. BMC Infectious Diseases  (2017) 17:732 Page 8 of 9
17. Vespa GN, Cunha FQ, Silva JS. Nitric oxide is involved in control of
Trypanosoma cruzi-induced parasitemia and directly kills the parasite in
vitro. Infect Immun. 1994;62(11):5177–82.
18. Padilla AM, Bustamante JM, Tarleton RL. CD8+ T cells in Trypanosoma cruzi
infection. Curr Opin Immunol. 2009;21(4):385–90.
19. Tarleton RL. CD8+ T cells in Trypanosoma cruzi infection. Semin
Immunopathol. 2015;37(3):233–8.
20. Vasconcelos JR, Dominguez MR, Neves RL, Ersching J, Araujo A, Santos LI,
Virgilio FS, Machado AV, Bruna-Romero O, Gazzinelli RT, et al. Adenovirus
vector-induced CD8(+) T effector memory cell differentiation and
recirculation, but not proliferation, are important for protective immunity
against experimental Trypanosoma cruzi infection. Hum Gene Ther. 2014;
25(4):350–63.
21. Cai CW, Blase JR, Zhang X, Eickhoff CS, Hoft DF. Th17 cells are more
protective than Th1 cells against the intracellular parasite Trypanosoma cruzi.
PLoS Pathog. 2016;12(10):e1005902.
22. Fernandes MC, Andrews NW. Host cell invasion by Trypanosoma cruzi: a
unique strategy that promotes persistence. FEMS Microbiol Rev. 2012;36(3):
734–47.
23. Nagajyothi F, Machado FS, Burleigh BA, Jelicks LA, Scherer PE, Mukherjee S,
Lisanti MP, Weiss LM, Garg NJ, Tanowitz HB. Mechanisms of Trypanosoma
cruzi persistence in Chagas disease. Cell Microbiol. 2012;14(5):634–43.
24. Revelli S, Gomez L, Wietzerbin J, Bottasso O, Basombrio MA. Levels of tumor
necrosis factor alpha, gamma interferon, and interleukins 4,6, and 10 as
determined in mice infected with virulent or attenuated strains of
Trypanosoma cruzi. Parasitol Res. 1999;85(2):147–50.
25. Basombrio MA. Trypanosoma cruzi: partial prevention of the natural
infection of guinea pigs with a killed parasite vaccine. Exp Parasitol. 1990;
71(1):1–8.
26. Basombrio MA, Arredes H. Long-term immunological response induced by
attenuated Trypanosoma cruzi in mice. J Parasitol. 1987;73(1):236–8.
27. Basombrio MA, Arredes H, Uncos DA, Rossi R, Alvarez E. Field trial of
vaccination against American trypanosomiasis (Chagas' disease) in domestic
guinea pigs. Am J Trop Med Hyg. 1987;37(1):57–62.
28. Basombrio MA, Arredes HR, Rossi R. Molina de Raspi E: Histopathological
and parasitological evidence of immunization of mice against challenge
with 17 wild isolates of Trypanosoma cruzi. Int J Parasitol. 1986;16(4):375–80.
29. Basombrio MA, Besuschio S. Trypanosoma cruzi culture used as vaccine to
prevent chronic Chagas' disease in mice. Infect Immun. 1982;36(1):351–6.
30. Basombrio MA, Besuschio S, Cossio PM. Side effects of immunization with
liver attenuated Trypanosoma cruzi in mice and rabbits. Infect Immun. 1982;
36(1):342–50.
31. Basombrio MA, Segura MA, Mora MC, Gomez L. Field trial of vaccination
against American trypanosomiasis (Chagas' disease) in dogs. Am J Trop
Med Hyg. 1993;49(1):143–51.
32. Perez Brandan C, Padilla AM, Xu D, Tarleton RL, Basombrio MA. Knockout of
the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able
to confer protection against a virulent challenge. PLoS Negl Trop Dis. 2011;
5(12):e1418.
33. Sanchez-Valdez FJ, Perez Brandan C, Ramirez G, Uncos AD, Zago MP, Cimino
RO, Cardozo RM, Marco JD, Ferreira A, Basombrio MA. A monoallelic
deletion of the TcCRT gene increases the attenuation of a cultured
Trypanosoma cruzi strain, protecting against an in vivo virulent challenge.
PLoS Negl Trop Dis. 2014;8(2):e2696.
34. Basombrío M, Besuschio S. Trypanosoma cruzi culture used as vaccine to
prevent chronic Chagas' disease in mice. Infect Immun. 1982;36(1):351–6.
35. Cardillo F, Voltarelli JC, Reed SG, Silva JS. Regulation of Trypanosoma cruzi
infection in mice by gamma interferon and interleukin 10: role of NK cells.
Infect Immun. 1996;64(1):128–34.
36. Marinho CR, Nunez-Apaza LN, Martins-Santos R, Bastos KR, Bombeiro AL,
Bucci DZ, Sardinha LR, Lima MR, Alvarez JM. IFN-gamma, but not nitric
oxide or specific IgG, is essential for the in vivo control of low-virulence
Sylvio X10/4 Trypanosoma cruzi parasites. Scand J Immunol. 2007;66(2–3):
297–308.
37. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1
reciprocally regulate Ig isotype production. Science. 1987;236(4804):944–7.
38. Umekita LF, Mota I. Role of the mononuclear phagocytic system in the
immune and nonspecific clearance of Trypanosoma cruzi bloodstream
trypomastigotes. Braz J Med Biol Res. 1989;22(12):1489–95.
39. Brodskyn CI, Silva AM, Takehara HA, Mota I. IgG subclasses responsible for
immune clearance in mice infected with Trypanosoma cruzi. Immunol Cell
Biol. 1989;67(Pt 6):343–8.
40. Machado FS, Martins GA, Aliberti JC, Mestriner FL, Cunha FQ, Silva JS.
Trypanosoma cruzi-infected cardiomyocytes produce chemokines and
cytokines that trigger potent nitric oxide-dependent trypanocidal activity.
Circulation. 2000;102(24):3003–8.
41. Marinho CR, Bastos KR, Sardinha LR, Grisotto MG, Lima MR, Alvarez JM.
Challenge of Trypanosoma cruzi chronically infected mice with
trypomastigotes activates the immune system and reduces subpatent
parasitemia levels. J Parasitol. 2004;90(3):516–23.
42. Lykens JE, Terrell CE, Zoller EE, Divanovic S, Trompette A, Karp CL, Aliberti J,
Flick MJ, Jordan MB. Mice with a selective impairment of IFN-gamma
signaling in macrophage lineage cells demonstrate the critical role of IFN-
gamma-activated macrophages for the control of protozoan parasitic
infections in vivo. J Immunol. 2010;184(2):877–85.
43. Aliberti JC, Souto JT, Marino AP, Lannes-Vieira J, Teixeira MM, Farber J,
Gazzinelli RT, Silva JS. Modulation of chemokine production and
inflammatory responses in interferon-gamma- and tumor necrosis factor-R1-
deficient mice during Trypanosoma cruzi infection. Am J Pathol. 2001;158(4):
1433–40.
44. Dos Santos VF, Pontes C, Dominguez MR, Ersching J, Rodrigues MM,
Vasconcelos JR. CD8(+) T cell-mediated immunity during Trypanosoma cruzi
infection: a path for vaccine development? Mediat Inflamm. 2014;2014:
243786.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Pérez Brandán et al. BMC Infectious Diseases  (2017) 17:732 Page 9 of 9
